PE20090987A1 - PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE

Info

Publication number
PE20090987A1
PE20090987A1 PE2008001380A PE2008001380A PE20090987A1 PE 20090987 A1 PE20090987 A1 PE 20090987A1 PE 2008001380 A PE2008001380 A PE 2008001380A PE 2008001380 A PE2008001380 A PE 2008001380A PE 20090987 A1 PE20090987 A1 PE 20090987A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition including
glucoside
derivative
carbonitrile
Prior art date
Application number
PE2008001380A
Other languages
Spanish (es)
Inventor
Klaus Dugi
Frank Himmelsbach
Michael Mark
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20090987A1 publication Critical patent/PE20090987A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN DERIVADO DE PIRAZOL-O-GLUCOSIDO DE FORMULA (I), EN COMBINACION CON UN INHIBIDOR DE DPP IV SELECCIONADO DE SITAGLIPTINA, VIDAGLIPTINA, SAXAGLIPTINA, ALOGLIPTINA, DENAGLIPTINA, (2S)-1-{[2-(5-METIL-2-FENILOXAZOL-4-IL)ETILAMINO]ACETIL}PIRROLIDIN-2-CARBONITRILO, (2S)-1-{[1,1-DIMETIL-3-(4-PIRIDIN-3-ILIMIDAZOL-1-IL)PROPILAMINO]ACETIL}PIRROLIDIN-2-CARBONITRILO; (S)-1-((2S, 3S, 11bS)-2-AMINO-9,10-DIMETOXI-1,3,4,7,11b-HEXAHIDRO-2H-PIRIDO[2,1-a]ISOQUINOLIN-3-IL)-4-FLUOROMETILPIRROLIDIN-2-ONA; ENTRE OTROS. DICHO COMPUESTO DE FORMULA (I) TIENE LOS SIGUIENTES SUSTITUYENTES: R1 ES ALCOXI C1-3; L1 Y L2 SON H O F Y R6 ES H, (ALQUIL C1-3)CARBONILO, (ALQUIL C1-6)OXICARBONILO, FENILOXICARBONILO, BENCILOXICARBONILO O BENCILCARBONILO. DICHA COMPOSICION ES ADECUADA PARA EL TRATAMIENTO O PREVENCION DE UNA O MAS AFECCIONES SELECCIONADAS DE DIABETES MELLITUS DE TIPO 1, DIABETES MELLITUS DE TIPO 2, TOLERANCIA ANORMAL A LA GLUCOSA, GLUCOSA SANGUINEA ANORMAL EN AYUNAS E HIPERGLUCEMIAREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING A PIRAZOLE-O-GLUCOSIDE DERIVATIVE OF FORMULA (I), IN COMBINATION WITH A DPP IV INHIBITOR SELECTED FROM SITAGLIPTINE, VIDAGLIPTIN, SAXAGLIPTIN, [2-DENAGLIPTIN-1, [2-ALOGLIPTIN] 2- (5-METHYL-2-PHENYLOXAZOLE-4-IL) ETHYLAMINE] ACETYL} PYRROLIDIN-2-CARBONITRILE, (2S) -1 - {[1,1-DIMETHYL-3- (4-PYRIDIN-3-ILIMIDAZOLE- 1-IL) PROPYLAMINO] ACETYL} PYRROLIDIN-2-CARBONITRILE; (S) -1 - ((2S, 3S, 11bS) -2-AMINO-9,10-DIMETOXY-1,3,4,7,11b-HEXAHYDRO-2H-PYRIDO [2,1-a] ISOQUINOLIN-3 -IL) -4-FLUOROMETHYLPYRROLIDIN-2-ONA; AMONG OTHERS. SAID COMPOUND OF FORMULA (I) HAS THE FOLLOWING SUBSTITUENTS: R1 IS ALCOXI C1-3; L1 AND L2 ARE H OR F AND R6 IS H, (C1-3 ALKYL) CARBONYL, (C1-6 ALKYL) OXYCARBONYL, PHENYLOXYCARBONYL, BENZYLOXYCARBONYL OR BENZYLCARBONYL. SUCH COMPOSITION IS ADEQUATE FOR THE TREATMENT OR PREVENTION OF ONE OR MORE SELECTED CONDITIONS OF TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, ABNORMAL GLUCOSE TOLERANCE, ABNORMAL BLOOD GLUCOSE IN FASTING AND HYPERGLYCEMIA

PE2008001380A 2007-08-16 2008-08-14 PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE PE20090987A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114461 2007-08-16

Publications (1)

Publication Number Publication Date
PE20090987A1 true PE20090987A1 (en) 2009-08-14

Family

ID=39870441

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001380A PE20090987A1 (en) 2007-08-16 2008-08-14 PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE

Country Status (6)

Country Link
AR (1) AR068102A1 (en)
CL (1) CL2008002424A1 (en)
PE (1) PE20090987A1 (en)
TW (1) TW200918078A (en)
UY (1) UY31290A1 (en)
WO (1) WO2009022009A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
TW200900094A (en) 2007-03-13 2009-01-01 Takeda Pharmaceutical Solid preparation
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
CL2008003653A1 (en) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (en) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Salt forms of organic compounds
EA022349B1 (en) 2009-02-13 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and a further antidiabetic agent and uses thereof
BR112012012641A2 (en) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-lVTAL INHIBITORS LIKE LINAGLIPTIN
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
AU2011268940B2 (en) 2010-06-24 2015-05-21 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
JP4424203B2 (en) * 2002-04-26 2010-03-03 味の素株式会社 Diabetes prevention and treatment
DK1638970T3 (en) * 2003-06-20 2011-01-03 Hoffmann La Roche Pyrid (2,1-A) -isoquinoline derivatives as DPP-IV inhibitors
PL1753748T3 (en) * 2004-05-12 2010-01-29 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
BRPI0516340A (en) * 2004-10-12 2008-09-16 Glenmark Pharmaceuticals Sa compound, pharmaceutical composition, method for treating a condition that is regulated or normalized via dpp-iv inhibition, method for treating a metabolic disorder, method for treating type ii diabetes, method for lowering blood glucose, method for treating and prophylaxis of a disease, method for treating undamaged insulin-resistant glucose tolerance, method for the manufacture of a pharmaceutical composition and process for the preparation of compounds
UY29694A1 (en) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDO
EP1942898B2 (en) * 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
PE20080251A1 (en) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
WO2007148185A2 (en) * 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
CL2008000133A1 (en) * 2007-01-19 2008-05-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND DERIVED FROM PIRAZOL-O-GLUCOSIDE COMBINED WITH AT LEAST A SECOND THERAPEUTIC AGENT; AND USE OF THE COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES, CATARATS, NEUROPATHY, MYOCARDIAL INFARTS, AND

Also Published As

Publication number Publication date
WO2009022009A1 (en) 2009-02-19
TW200918078A (en) 2009-05-01
CL2008002424A1 (en) 2009-09-11
AR068102A1 (en) 2009-11-04
UY31290A1 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
PE20090987A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A DERIVATIVE OF PIRAZOL-O-GLUCOSIDE
AR064969A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A PIRAZOL DERIVATIVE -OR- GLUCOSIDE
AR083679A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
UY27518A1 (en) NEW PIRROLIDINE DERIVATIVES
UY31291A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DERIVATIVE OF PIRAZOL-0-GLUCOSIDO
AR062111A1 (en) DERIVATIVES OF BETA-D-GLUCOPIRANOSIL INDOL, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS ANTI-DIABETIC AGENTS.
ECSP109977A (en) Pharmaceutical composition comprising a benzene derivative substituted with glucopyranosyl.
UY27666A1 (en) NEW DERIVATIVES OF PIRIDINA AND QUINOLINA
UY31295A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY AN SGLT2 INHIBITOR
PE20110841A1 (en) CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-THENYLMETHYL] BENZENE HEMIHYDRATE
ECSP066653A (en) DERIVATIVES OF BENCENOSULFONILAMINO-PIRIDIN-2-IL AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (II-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY
AR067538A1 (en) INHIBIDORTES OF THE 11 BETA -HYDROXIESTEROID-DEHYDROGENase
AR067770A1 (en) DERIVATIVES OF TIAZOL AND DITIAZOL FOR THE TREATMENT OF DIABETES
EA201001595A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
CL2011001027A1 (en) Compounds derived from 1- (benzo [d] [1,3] dioxol-6-yl] -n (1h-indol-5-yl) cyclopropane carboxamide; abc modulators; pharmaceutical composition comprising them; in vitro method of increasing abc transporters; pharmaceutical kit; and its use in the treatment of cystic fibrosis, metabolic problems, of the snc, among others.
AR064736A1 (en) GPCR AGONISTS
NO20055680L (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
PE20110060A1 (en) CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE
CL2009001059A1 (en) Compounds derived from substituted 1,3-oxazin-2-one-3.6, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that includes them; Useful in the treatment of diseases such as diabetes mellitus, among others.
ATE442349T1 (en) DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
ECSP099037A (en) METABOLISM MODULATORS AND TREATMENT OF METABOLIC DISORDERS
PE20110288A1 (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANE-2,3,4-TRIOL
PE20091425A1 (en) AMINOTIAZOLE DERIVATIVES
AR039281A1 (en) STABILIZING BLENDS
ATE427926T1 (en) CYCLOALKYLAMIN DERIVATIVES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal